A study to evaluate the effect of celecoxib as add-on to olanzapine therapy in schizophrenia

Baheti, Tushar; Nischal, Anil; Khattri, Sanjay; Arya, Amit; Pant, Kamlesh Kumar

doi:10.1016/j.schres.2013.03.017

Cited by 10 publications

(6 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Very recently, Baheti et al [ 123 ] have conducted an open-labeled, prospective, 6-week controlled trial to evaluate the effect of celecoxib as add-on to olanzapine therapy in acute exacerbation schizophrenics. Beneficial effects in positive, negative, and general psychopathology and total scores on PANSS have been reported, maybe for the short-term period of the trial and for the use of ICD-10 criteria for the diagnosis of schizophrenia.…”

Section: Discussionmentioning

confidence: 99%

Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials

Marini

Berardis²,

Vellante

et al. 2016

Mediators of Inflammation

View full text Add to dashboard Cite

Schizophrenia is a severe, chronic and debilitating mental disorder. Past literature has reported various hypotheses about the psychopathology of schizophrenia. Recently, a growing literature has been trying to explain the role of inflammation in the etiopathogenesis of schizophrenia. In the past, numerous immune modulation and anti-inflammatory treatment options have been proposed for schizophrenia, but sometimes the results were inconsistent. Electronic search was carried out in November 2015. PubMed and Scopus databases have been used to find studies to introduce in this review. Only randomized-placebo-controlled add-on trials were taken into account. In this way, six articles were obtained for the discussion. Celecoxib showed beneficial effects mostly in early stages of schizophrenia. In chronic schizophrenia, the data are controversial, possibly in part for methodological reasons.

show abstract

Section: Discussionmentioning

confidence: 99%

Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials

Marini

Berardis²,

Vellante

et al. 2016

Mediators of Inflammation

View full text Add to dashboard Cite

show abstract

“…The remaining PKA gene set molecule, PTGS2 , encoding the COX-2 protein, is gaining attention as a schizophrenia drug target because inhibitors appear to be beneficial in symptom treatment (Müller et al, 2010 ; Baheti et al, 2013 ). PTGS2 mRNA expression is altered in the prefrontal cortex of patients (Tang et al, 2012 ).…”

Section: Discussionmentioning

confidence: 99%

Meta gene set enrichment analyses link miR-137-regulated pathways with schizophrenia risk

et al. 2015

View full text Add to dashboard Cite

Background: A single nucleotide polymorphism (SNP) within MIR137, the host gene for miR-137, has been identified repeatedly as a risk factor for schizophrenia. Previous genetic pathway analyses suggest that potential targets of this microRNA (miRNA) are also highly enriched in schizophrenia-relevant biological pathways, including those involved in nervous system development and function.Methods: In this study, we evaluated the schizophrenia risk of miR-137 target genes within these pathways. Gene set enrichment analysis of pathway-specific miR-137 targets was performed using the stage 1 (21,856 subjects) schizophrenia genome wide association study data from the Psychiatric Genomics Consortium and a small independent replication cohort (244 subjects) from the Mind Clinical Imaging Consortium and Northwestern University.Results: Gene sets of potential miR-137 targets were enriched with variants associated with schizophrenia risk, including target sets involved in axonal guidance signaling, Ephrin receptor signaling, long-term potentiation, PKA signaling, and Sertoli cell junction signaling. The schizophrenia-risk association of SNPs in PKA signaling targets was replicated in the second independent cohort.Conclusions: These results suggest that these biological pathways may be involved in the mechanisms by which this MIR137 variant enhances schizophrenia risk. SNPs in targets and the miRNA host gene may collectively lead to dysregulation of target expression and aberrant functioning of such implicated pathways. Pathway-guided gene set enrichment analyses should be useful in evaluating the impact of other miRNAs and target genes in different diseases.

show abstract

“…In a similar study add-on aspirin given to patients improved symptoms, however only in patients with high CRP serum levels [ 159 ]. In patients with an acute exacerbation of schizophrenia treatment with cyclooxygenase-2 inhibitor, celecoxib in addition to risperidone led to a significant improvement of positive and negative symptoms in excess of the relief assignable to the antipsychotic [ 154 , 161 – 163 ]. On the other hand, when patients who had suffered from symptoms for at least three months despite treatment, rather than patients with an acute exacerbation of psychosis, were treated with celecoxib in a similar study design, no difference in outcome was found [ 164 ].…”

Section: Modulating Neuroinflammation To Treat Psychiatric Diseasementioning

confidence: 99%

Modulating Neuroinflammation to Treat Neuropsychiatric Disorders

Radtke

Chapman

Hall

et al. 2017

BioMed Research International

View full text Add to dashboard Cite

Neuroinflammation is recognised as one of the potential mechanisms mediating the onset of a broad range of psychiatric disorders and may contribute to nonresponsiveness to current therapies. Both preclinical and clinical studies have indicated that aberrant inflammatory responses can result in altered behavioral responses and cognitive deficits. In this review, we discuss the role of inflammation in the pathogenesis of neuropsychiatric disorders and ask the question if certain genetic copy-number variants (CNVs) associated with psychiatric disorders might play a role in modulating inflammation. Furthermore, we detail some of the potential treatment strategies for psychiatric disorders that may operate by altering inflammatory responses.

show abstract

A study to evaluate the effect of celecoxib as add-on to olanzapine therapy in schizophrenia

Cited by 10 publications

References 7 publications

Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials

Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials

Meta gene set enrichment analyses link miR-137-regulated pathways with schizophrenia risk

Modulating Neuroinflammation to Treat Neuropsychiatric Disorders

Contact Info

Product

Resources

About